norgestimate has been researched along with Thrombophlebitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwingl, PJ; Shelton, J | 1 |
| Hamulyak, K; Heijnen, P; Hemker, HC; Nicolaes, GA; Rosing, J; Tans, G; Thomassen, MC; van der Ploeg, PM; van Oerle, R | 1 |
| Bloemenkamp, KW; Helmerhorst, FM; Rosendaal, FR; Vandenbroucke, JP | 1 |
1 review(s) available for norgestimate and Thrombophlebitis
| Article | Year |
|---|---|
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation.
Topics: Bias; Blood Coagulation; Contraceptives, Oral, Synthetic; Drug Resistance; Factor V; Female; Humans; Norgestrel; Progesterone Congeners; Protein C; Risk Factors; Thrombophlebitis | 1997 |
2 other study(ies) available for norgestimate and Thrombophlebitis
| Article | Year |
|---|---|
Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
Topics: Adolescent; Adult; Age Factors; Cohort Studies; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Desogestrel; Female; Humans; Incidence; Levonorgestrel; Myocardial Infarction; Norethindrone; Norgestrel; Risk Factors; Thrombophlebitis; United States | 1997 |
Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Topics: Adolescent; Adult; Aged; Contraceptives, Oral, Combined; Desogestrel; Factor V; Female; Hemostasis; Heterozygote; Humans; Levonorgestrel; Male; Middle Aged; Norgestrel; Norpregnenes; Protein C; Thrombin; Thrombophlebitis | 1997 |